Protalix BioTherapeutics Inc (PLX)
1.405
+0.16
(+13.31%)
USD |
NYAM |
Nov 14, 16:00
1.40
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics Research and Development Expense (Quarterly): 2.961M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.961M |
| March 31, 2024 | 2.887M |
| December 31, 2023 | 3.102M |
| September 30, 2023 | 3.669M |
| June 30, 2023 | 4.475M |
| March 31, 2023 | 5.847M |
| December 31, 2022 | 5.617M |
| September 30, 2022 | 7.386M |
| June 30, 2022 | 7.579M |
| March 31, 2022 | 8.767M |
| December 31, 2021 | 7.641M |
| September 30, 2021 | 7.282M |
| June 30, 2021 | 7.689M |
| March 31, 2021 | 7.122M |
| December 31, 2020 | 10.95M |
| September 30, 2020 | 7.688M |
| June 30, 2020 | 9.186M |
| March 31, 2020 | 10.34M |
| December 31, 2019 | 9.595M |
| September 30, 2019 | 10.00M |
| June 30, 2019 | 13.32M |
| March 31, 2019 | 11.70M |
| December 31, 2018 | 9.575M |
| September 30, 2018 | 10.07M |
| June 30, 2018 | 7.241M |
| Date | Value |
|---|---|
| March 31, 2018 | 6.443M |
| December 31, 2017 | 8.99M |
| September 30, 2017 | 6.389M |
| June 30, 2017 | 8.826M |
| March 31, 2017 | 4.629M |
| December 31, 2016 | 5.708M |
| September 30, 2016 | 5.056M |
| June 30, 2016 | 7.819M |
| March 31, 2016 | 6.025M |
| December 31, 2015 | 6.407M |
| September 30, 2015 | 3.952M |
| June 30, 2015 | 4.694M |
| March 31, 2015 | 4.972M |
| December 31, 2014 | 5.09M |
| September 30, 2014 | 6.105M |
| June 30, 2014 | 4.962M |
| March 31, 2014 | 6.067M |
| December 31, 2013 | 8.594M |
| September 30, 2013 | 5.637M |
| June 30, 2013 | 6.458M |
| March 31, 2013 | 5.323M |
| December 31, 2012 | 6.627M |
| September 30, 2012 | 6.363M |
| June 30, 2012 | 8.855M |
| March 31, 2012 | 6.844M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.887M
Minimum
Mar 2024
10.95M
Maximum
Dec 2020
6.831M
Average
7.386M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| Accuray Inc | 9.529M |
| Aethlon Medical Inc | -- |
| Predictive Oncology Inc | -- |
| bluebird bio Inc | 25.16M |
| AIM ImmunoTech Inc | 1.145M |